Camurus AB
CAMX
株式のランク
#3989
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
株価
$68.08
時価総額
$4.05B
変化（1日）
0.75%
変化（1年）
-2.27%
国
SE
取引 Camurus AB (CAMX)
カテゴリー
Healthcare
Camurus AB（CAMX）の発行済株式数
October 2026 時点の発行済株式数 0
Camurus AB の最新の財務報告および株価によると、現在の発行済株式数は 0 です。October 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Camurus AB（CAMX）の発行済株式数の履歴（2012 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2025 | 59.23M | 2.11% |
| 2024 | 58.01M | 4.56% |
| 2023 | 55.48M | 0.74% |
| 2022 | 55.07M | 1.13% |
| 2021 | 54.45M | 3.36% |
| 2020 | 52.68M | 13.30% |
| 2019 | 46.50M | 14.32% |
| 2018 | 40.67M | -0.12% |
| 2017 | 40.72M | 0.00% |
| 2016 | 40.72M | 40.70% |
| 2015 | 28.94M | -29.26% |
| 2014 | 40.91M | 0.00% |
| 2013 | 40.91M | 0.00% |
| 2012 | 40.91M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| - | - |
CH
|
